Halozyme Therapeutic (HALO) Stock Price, Quote & News

Company Profile

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 794 8889

Fax: 858 704 8311

Website: halozyme.com

Address:

12390 El Camino Real, San Diego, United States

Sean29md Jul. 21 at 7:22 PM

$HALO Benchmark reiterated a Buy rating and $90 price target on Halozyme Therapeutic https://www.investing.com/news/analyst-ratings/benchmark-reiterates-halozyme-stock-buy-rating-on-incyte-deal-93CH-4803699

0 · Reply

justAtool Jul. 21 at 3:01 PM

$HALO

0 · Reply

JFDI Jul. 21 at 2:48 PM

$HALO C&H on the daily

0 · Reply

Sean29md Jul. 21 at 1:21 PM

$HALO HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $95 Price Target 6:23 AM ET 07/21/2026 | Benzinga HALO

0 · Reply

jw56502 Jul. 20 at 12:21 PM

$HALO is going to have to update its slides for expected deal making with their technology in 2026 https://www.prnewswire.com/news-releases/halozyme-announces-global-collaboration-and-license-agreement-with-incyte-to-support-the-development-of-subcutaneous-formulations-of-inca033989-using-its-enhanze-technology-302829283.html

0 · Reply

StockConsultant Jul. 17 at 3:51 AM

A good day for stocks $BLDR $DBI $HALO $SPG and $VRTX rallying off the support areas, from Stocks to Watch at https://stockconsultant.com/?HALO

0 · Reply

Doozio Jul. 16 at 2:12 PM

$TSLA have no fear da $HALO is here to protect YO on a Thursday 🐑 low cuz da 🐒🍌🧠 is baaaahck ENTA 🐒🍌🧠⏰♾️ ❤️👑🌈🦄

1 · Reply

Sean29md Jul. 15 at 1:28 PM

$HALO Genmab Reports Q2 DARZALEX Net Sales Of $4.207B, Up 17.6% YoY 6:25 AM ET 07/15/2026 | Benzinga

0 · Reply

French_Vibe Jul. 15 at 11:51 AM

$HALO https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-reports-Q2-2026-results-raises-2026-outlook/default.aspx

0 · Reply

Sean29md Jul. 13 at 3:29 PM

$HALO https://x.com/alchemistuniq/status/2076630684404166697?s=46&t=w846wB8JWUjkkF_HpZVw_w

0 · Reply

Halozyme's Partnerships, Earnings Growth See Shares Near All-Time Highs

2026-07-20T12:05:48.000Z - 2 days ago

Halozyme announces global collaboration, license agreement with Incyte

INCY

Jul 20, 2026, 8:00 AM EDT - 2 days ago

Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology

INCY

Jun 30, 2026, 4:02 PM EDT - 21 days ago

Halozyme Appoints David Ramsay as President Drug Delivery

2026-06-22T13:43:30.000Z - 4 weeks ago

LifeMD partners with Halozyme subsidiary for exclusive testosterone program

LFMD

Jun 15, 2026, 10:53 AM EDT - 5 weeks ago

20 growth stocks priced as value stocks

ADMA AMG ANIP ARR BILL CG DAN

Jun 15, 2026, 6:00 AM EDT - 5 weeks ago

Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029

2026-05-12T16:13:22.000Z - 2 months ago

Halozyme price target lowered to $93 from $96 at Morgan Stanley

May 11, 2026, 4:30 PM EDT - 2 months ago

Halozyme Therapeutics Earnings Call Transcript: Q1 2026

May 11, 2026, 4:30 PM EDT - 2 months ago

Halozyme Therapeutics Earnings release: Q1 2026

May 11, 2026, 4:30 PM EDT - 2 months ago

Halozyme Therapeutics Quarterly report: Q1 2026

May 11, 2026, 4:30 PM EDT - 2 months ago

Halozyme Therapeutics Slides: Q1 2026

May 11, 2026, 4:01 PM EDT - 2 months ago

HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE

2026-05-07T19:48:39.000Z - 2 months ago

Halozyme announces global collaboration and license agreement with GSK

GSK

May 7, 2026, 9:00 AM EDT - 2 months ago

Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets

2026-05-07T06:12:19.000Z - 2 months ago

Halozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis

ORKA

May 6, 2026, 8:00 AM EDT - 2 months ago

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

ORKA

May 5, 2026, 12:00 PM EDT - 2 months ago

Halozyme Therapeutics Transcript: AGM 2026

Apr 30, 2026, 4:30 PM EDT - 2 months ago

Halozyme to Report First Quarter 2026 Financial and Operating Results

2026-04-30T17:01:40.000Z - 2 months ago

Halozyme names Darren Snellgrove as CFO

JNJ

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Halozyme Appoints Darren Snellgrove as Chief Financial Officer

2026-04-29T10:25:50.000Z - 3 months ago

Halozyme price target raised to $95 from $90 at H.C. Wainwright

2026-04-21T12:51:13.000Z - 3 months ago

Halozyme price target raised to $96 from $94 at Morgan Stanley

2026-04-07T12:23:24.000Z - 3 months ago

Halozyme enters global global collaboration and license agreement with Vertex

VRTX

Apr 7, 2026, 8:00 AM EDT - 3 months ago

Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology

Mar 23, 2026, 8:00 AM EDT - 4 months ago

Halozyme Therapeutics Proxy statement: Proxy filing

Mar 23, 2026, 8:00 AM EDT - 4 months ago

Halozyme Therapeutics Proxy statement: Proxy filing

2026-03-12T12:38:03.000Z - 4 months ago

Halozyme names David Ramsay as Interim CFO

Mar 12, 2026, 8:30 AM EDT - 4 months ago

Halozyme Appoints David Ramsay as Interim Chief Financial Officer

Mar 11, 2026, 10:45 AM EDT - 4 months ago

Halozyme Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 1:00 PM EDT - 4 months ago

Halozyme Therapeutics Transcript: Leerink Global Healthcare Conference 2026

$U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma$

Mar 6, 2026, 8:00 AM EST - 4 months ago

U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma

Mar 3, 2026, 11:10 AM EST - 5 months ago

Halozyme Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 8:30 AM EST - 5 months ago

Halozyme to Participate in Upcoming Investor Conferences

2026-02-19T13:43:22.000Z - 5 months ago

Halozyme price target raised to $94 from $78 at Morgan Stanley

2026-02-19T13:36:39.000Z - 5 months ago

Halozyme price target raised to $90 from $75 at Benchmark

2026-02-19T11:32:57.000Z - 5 months ago

Halozyme price target raised to $75 from $65 at Wells Fargo

Feb 17, 2026, 4:30 PM EST - 5 months ago

Halozyme Therapeutics Earnings Call Transcript: Q4 2025

Feb 17, 2026, 4:30 PM EST - 5 months ago

Halozyme Therapeutics Annual report: Q4 2025

Feb 17, 2026, 4:30 PM EST - 5 months ago

Halozyme Therapeutics Earnings release: Q4 2025

Feb 17, 2026, 4:30 PM EST - 5 months ago

Halozyme Therapeutics Slides: Q4 2025

2026-02-17T21:05:28.000Z - 5 months ago

Halozyme reports Q4 EPS 24c vs. $1.26 last year

Feb 17, 2026, 4:01 PM EST - 5 months ago

HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE

Feb 10, 2026, 4:05 PM EST - 5 months ago

Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results

Jan 28, 2026, 8:30 AM EST - 6 months ago

Halozyme Therapeutics Transcript: Investor update

Jan 28, 2026, 8:30 AM EST - 6 months ago

Halozyme Therapeutics Press release: Investor update

Jan 28, 2026, 8:30 AM EST - 6 months ago

Halozyme Therapeutics Slides: Investor update

Jan 28, 2026, 6:30 AM EST - 6 months ago

Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance

Jan 20, 2026, 4:05 PM EST - 6 months ago

Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update

Jan 8, 2026, 8:00 AM EST - 6 months ago

Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®

Jan 5, 2026, 7:00 AM EST - 7 months ago

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

SKYE

Dec 18, 2025, 7:00 AM EST - 7 months ago

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

Dec 8, 2025, 4:05 PM EST - 8 months ago

Jim Lang Elected to Halozyme's Board of Directors

Dec 4, 2025, 2:22 PM EST - 8 months ago

Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case

Dec 4, 2025, 1:26 PM EST - 8 months ago

Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany

Dec 2, 2025, 1:20 PM EST - 8 months ago

Halozyme Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 25, 2025, 8:30 AM EST - 8 months ago

Halozyme to Participate in the 8th Annual Evercore Healthcare Conference

Nov 18, 2025, 8:50 AM EST - 8 months ago

Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery

Nov 17, 2025, 7:00 AM EST - 8 months ago

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

MRUS

Nov 10, 2025, 1:00 PM EST - 9 months ago

The Big 3: OKLO, HALO, V

OKLO V

Nov 7, 2025, 8:30 AM EST - 9 months ago

FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma

Nov 6, 2025, 11:37 PM EST - 9 months ago

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Nov 5, 2025, 4:05 PM EST - 9 months ago

Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Nov 3, 2025, 4:30 PM EST - 9 months ago

Halozyme Therapeutics Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:30 PM EST - 9 months ago

Halozyme Therapeutics Quarterly report: Q3 2025

Nov 3, 2025, 4:30 PM EST - 9 months ago

Halozyme Therapeutics Earnings release: Q3 2025

Nov 3, 2025, 4:30 PM EST - 9 months ago

Halozyme Therapeutics Slides: Q3 2025

Nov 3, 2025, 4:01 PM EST - 9 months ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

Oct 21, 2025, 8:30 AM EDT - 9 months ago

Halozyme to Report Third Quarter 2025 Financial and Operating Results

Oct 10, 2025, 8:35 AM EDT - 10 months ago

Strong And Rising: Halozyme Therapeutics Stock May Have More Upside

Oct 1, 2025, 8:30 AM EDT - 10 months ago

Halozyme Therapeutics Transcript: M&A Announcement

Oct 1, 2025, 8:30 AM EDT - 10 months ago

Halozyme Therapeutics Press release: M&A Announcement

Oct 1, 2025, 8:30 AM EDT - 10 months ago

Halozyme Therapeutics Slides: M&A Announcement

Oct 1, 2025, 7:16 AM EDT - 10 months ago

Halozyme to buy Elektrofi for $750 million to expand drug delivery lineup

Oct 1, 2025, 7:00 AM EDT - 10 months ago

Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s

Sep 8, 2025, 7:45 AM EDT - 11 months ago

Halozyme Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 4, 2025, 1:30 PM EDT - 11 months ago

Halozyme Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 29, 2025, 2:01 PM EDT - 11 months ago

Identify Superstar Stocks Like Halozyme with Money Flows

Aug 28, 2025, 8:30 AM EDT - 11 months ago

Halozyme to Participate at Upcoming Investor Conferences

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Halozyme Therapeutics Earnings Call Transcript: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Halozyme Therapeutics Quarterly report: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Halozyme Therapeutics Earnings release: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Halozyme Therapeutics Slides: Q2 2025

Aug 5, 2025, 4:01 PM EDT - 1 year ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS

Jul 23, 2025, 11:36 AM EDT - 1 year ago

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

Jul 22, 2025, 8:30 AM EDT - 1 year ago

Halozyme to Report Second Quarter 2025 Financial and Operating Results

Jun 30, 2025, 4:05 PM EDT - 1 year ago

Halozyme Therapeutics Added to Russell 1000® Index

Jun 20, 2025, 1:15 PM EDT - 1 year ago

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Jun 9, 2025, 10:00 AM EDT - 1 year ago

Halozyme Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

May 28, 2025, 8:30 AM EDT - 1 year ago

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

May 13, 2025, 7:20 PM EDT - 1 year ago

Halozyme Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 6, 2025, 4:30 PM EDT - 1 year ago

Halozyme Therapeutics Earnings Call Transcript: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Halozyme Therapeutics Quarterly report: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Halozyme Therapeutics Earnings release: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Halozyme Therapeutics Slides: Q1 2025

May 6, 2025, 4:01 PM EDT - 1 year ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

May 5, 2025, 5:15 PM EDT - 1 year ago

Halozyme to Participate in the BofA Securities 2025 Healthcare Conference

Apr 28, 2025, 8:30 AM EDT - 1 year ago

Halozyme to Report First Quarter 2025 Financial and Operating Results

Apr 28, 2025, 7:30 AM EDT - 1 year ago

Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Apr 24, 2025, 8:30 AM EDT - 1 year ago

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation

Apr 10, 2025, 6:15 PM EDT - 1 year ago

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

Sean29md Jul. 21 at 7:22 PM

0 · Reply

justAtool Jul. 21 at 3:01 PM

$HALO

0 · Reply

JFDI Jul. 21 at 2:48 PM

$HALO C&H on the daily

0 · Reply

Sean29md Jul. 21 at 1:21 PM

$HALO HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $95 Price Target 6:23 AM ET 07/21/2026 | Benzinga HALO

0 · Reply

jw56502 Jul. 20 at 12:21 PM

0 · Reply

StockConsultant Jul. 17 at 3:51 AM

A good day for stocks $BLDR $DBI $HALO $SPG and $VRTX rallying off the support areas, from Stocks to Watch at https://stockconsultant.com/?HALO

0 · Reply

Doozio Jul. 16 at 2:12 PM

$TSLA have no fear da $HALO is here to protect YO on a Thursday 🐑 low cuz da 🐒🍌🧠 is baaaahck ENTA 🐒🍌🧠⏰♾️ ❤️👑🌈🦄

1 · Reply

Sean29md Jul. 15 at 1:28 PM

$HALO Genmab Reports Q2 DARZALEX Net Sales Of $4.207B, Up 17.6% YoY 6:25 AM ET 07/15/2026 | Benzinga

0 · Reply

French_Vibe Jul. 15 at 11:51 AM

$HALO https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-reports-Q2-2026-results-raises-2026-outlook/default.aspx

0 · Reply

Sean29md Jul. 13 at 3:29 PM

$HALO https://x.com/alchemistuniq/status/2076630684404166697?s=46&t=w846wB8JWUjkkF_HpZVw_w

0 · Reply

kej32 Jul. 6 at 4:06 PM

$HALO We are definitely back! Can’t say I’m surprised. It was only a matter of time. This will be a $+100 soon enough!

0 · Reply

topstockalerts Jul. 2 at 11:57 PM

Halozyme Therapeutics announced the departure of Chief Operating Officer Cortney Caudill, according to a Form 8-K filed with the U.S. Securities and Exchange Commission. The company said Caudill stepped down from her roles as Senior Vice President and Chief Operating Officer, effective June 30, 2026. Halozyme thanked her for her contributions during her tenure but did not disclose the reason for her departure, stating only that the filing reflected the executive leadership change. The company also did not name an interim or permanent successor or provide a timeline for filling the position. No additional changes to Halozyme's executive leadership or business strategy were announced alongside the filing. $HALO

0 · Reply

Jblack500 Jul. 2 at 11:03 PM

$HALO snuck that coo release in right before long holiday weekend. Worth adding to on a cool down before heading higher. I lightened up yesterday and was looking to add back 6 to 8% below my sell point. Thought ibb needed a short breather before heading higher but it continued to press up today

0 · Reply

Doozio Jul. 2 at 5:51 PM

Da $HALO shall protect Yo ENTA 🐒🍌🧠⏰♾️ AAOI. No moar AEHR balls.

0 · Reply

JFDI Jun. 30 at 1:27 PM

$HALO alerts at 71.5, 74.5 and 78.5. Would like to see price tighten up before highs.

0 · Reply

Sean29md Jun. 30 at 1:50 AM

$HALO https://www.cnbc.com/video/2026/06/29/final-trade-halo-baba-googl-spcx.html

0 · Reply

Sean29md Jun. 30 at 1:38 AM

$HALO On June 26, 2026, Jim Cramer and Jeff Marks of the https://www.cnbc.com/investingclub/morning-meeting/ specifically highlighted Halozyme Therapeutics, pointing to its extended product revenue runway.

0 · Reply

Doozio Jun. 29 at 10:10 PM

Or they go Thursday 🐑 in da $FATE of da YO then out of the tightness da $HALO protects YO ENTA 🐒🍌🧠⏰♾️

0 · Reply

JR603 Jun. 29 at 7:10 PM

$HALO FROM AI - PTAB Rulings: A Major Victory for Halozyme (June 29) The U.S. Patent Trial and Appeal Board (PTAB) issued a significant ruling.The Decision: The Board rejected Merck's arguments and upheld Halozyme’s challenged claims, ruling that Merck failed to prove they were "obvious".The Takeaway: The PTAB concluded that modifying the specific molecular structures in question would have required "undue experimentation" by prior art standards. This is a massive defensive win for Halozyme, preserving its core patent fortress as the broader District Court case moves forward in New Jersey.

1 · Reply

Jblack500 Jun. 29 at 6:19 PM

$GILD $HALO $ANIP $MRK gild added 125.8...the current basket, also holding ELAN ARWR

0 · Reply

kej32 Jun. 29 at 4:56 PM

$HALO ok looks like you are now ready! Just had to be patient!!!

0 · Reply

Doozio Jun. 26 at 1:48 PM

Have no fear the $HALO is here to protect YO. Now let’s get $NUTX ONTO 🐒🍌🧠⏰♾️

0 · Reply

Market Cap	9.14B
Revenue (ttm)	1.40B
Net Income (ttm)	316.89M
EPS (ttm)	N/A
PE Ratio	18.39
Forward PE	10.32
Profit Margin	22.69%
Debt to Equity Ratio	9.76

Volume	1,273,000
Avg Vol	1,929,974
Day's Range	N/A - N/A
Shares Out	118.61M
Stochastic %K	59%
Beta	0.84
Analysts	Sell
Price Target	$83.82